Sitagliptin and Fractures in Type 2 Diabetes: A Nationwide Population-Based Propensity-Matching Study

Background: Sitagliptin, a dipeptidyl peptidase-4 inhibitor possibly affects bone turnover. We conducted this cohort study to determine whether sitagliptin is associated with an increased risk of fracture. Methods: The sitagliptin cohort included 1,578 patients aged 20 years and above. The nonsitagl...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Front Pharmacol
Glavni autori: Lin, Shih-Yi, Hsu, Wu-Huei, Lin, Cheng-Chieh, Lin, Cheng-Li, Tsai, Chun-Hao, Yeh, Hung-Chieh, Hsu, Chung-Y., Kao, Chia-Hung
Format: Artigo
Jezik:Inglês
Izdano: Frontiers Media S.A. 2018
Teme:
Pharmacology
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6025224/
https://ncbi.nlm.nih.gov/pubmed/29988467
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2018.00677
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items